Randhawa Simrat 4

What Happened

• Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics (DNTH), was granted a derivative award covering 150,000 underlying shares on 2026-02-03. The reported acquisition price is $0.00 (no cash paid at grant). This is an award/grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-02-03; filing date: 2026-02-04 (timely filing).
• Transaction type/code: Award/Grant (A); reported price per share: $0.00.
• Shares underlying award: 150,000 common shares (derivative securities).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Award vests in equal monthly installments over four years beginning January 1, 2026, subject to continued service (per filing footnote).

Context

• This was a grant of derivative securities (an equity award) — not a sale or exercise — so it does not reflect an immediate cash transaction or disposition. The vesting schedule means shares will be delivered over time if Randhawa remains employed.